-
1
-
-
4644230820
-
The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
DOI 10.1378/chest.126.3-suppl.204S
-
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004). (Pubitemid 39297955)
-
(2004)
Chest
, vol.126
, Issue.SUPPL. 3
-
-
Ansell, J.1
Hirsh, J.2
Poller, L.3
Bussey, H.4
Jacobson, A.5
Hijlek, E.6
-
2
-
-
81855169543
-
Emergency hospitalizations for adverse drug events in older Americans
-
Budnitz, D.S., Lovegrove, M.C., Shehab, N. & Richards, C.L. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002-2012 (2011).
-
(2011)
N. Engl. J. Med
, vol.365
, pp. 2002-2012
-
-
Budnitz, D.S.1
Lovegrove, M.C.2
Shehab, N.3
Richards, C.L.4
-
3
-
-
77954492897
-
Warfarin and vitamin K intake in the era of pharmacogenetics
-
Lurie, Y., Loebstein, R., Kurnik, D., Almog, S. & Halkin, H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br. J. Clin. Pharmacol. 70, 164-170 (2010).
-
(2010)
Br. J. Clin. Pharmacol
, vol.70
, pp. 164-170
-
-
Lurie, Y.1
Loebstein, R.2
Kurnik, D.3
Almog, S.4
Halkin, H.5
-
4
-
-
83055174032
-
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants
-
Cavallari, L.H., Shin, J. & Perera, M.A. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31, 1192-1207 (2011).
-
(2011)
Pharmacotherapy
, vol.31
, pp. 1192-1207
-
-
Cavallari, L.H.1
Shin, J.2
Perera, M.A.3
-
5
-
-
66849132349
-
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
-
McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. & Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009).
-
(2009)
Mol. Pharmacol
, vol.75
, pp. 1337-1346
-
-
McDonald, M.G.1
Rieder, M.J.2
Nakano, M.3
Hsia, C.K.4
Rettie, A.E.5
-
6
-
-
42149188553
-
CYP4F2 genetic variant alters required warfarin dose
-
Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
-
(2008)
Blood
, vol.111
, pp. 4106-4112
-
-
Caldwell, M.D.1
-
7
-
-
49849102081
-
The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure
-
Fava, C. et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-380 (2008).
-
(2008)
Hypertension
, vol.52
, pp. 373-380
-
-
Fava, C.1
-
8
-
-
84864488076
-
Hypertension cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?
-
Fava, C., Ricci, M., Melander, O. & Minuz, P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat. 98, 75-85 (2012).
-
(2012)
Prostaglandins Other Lipid Mediat
, vol.98
, pp. 75-85
-
-
Fava, C.1
Ricci, M.2
Melander, O.3
Minuz, P.4
-
9
-
-
79961106952
-
Association of apolipoprotein e genotype with duration of time to achieve a stable warfarin dose in African-American patients
-
Cavallari, L.H. et al. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 31, 785-792 (2011).
-
(2011)
Pharmacotherapy
, vol.31
, pp. 785-792
-
-
Cavallari, L.H.1
-
10
-
-
79958108633
-
Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population
-
Chan, S.L. et al. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. Thromb. Haemost. 105, 1100-1102 (2011).
-
(2011)
Thromb. Haemost
, vol.105
, pp. 1100-1102
-
-
Chan, S.L.1
-
11
-
-
51649110496
-
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
-
Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
-
(2008)
Blood
, vol.112
, pp. 1022-1027
-
-
Cooper, G.M.1
-
12
-
-
77951589703
-
Clinical assessment incorporating a personal genome
-
Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
-
(2010)
Lancet
, vol.375
, pp. 1525-1535
-
-
Ashley, E.A.1
-
13
-
-
79955910555
-
Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient
-
Ciccacci, C. et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet. Genomics 21, 344-346 (2011).
-
(2011)
Pharmacogenet. Genomics
, vol.21
, pp. 344-346
-
-
Ciccacci, C.1
-
14
-
-
78650057287
-
Genetic and bioenvironmental factors associated with warfarin response in Colombian patients
-
Isaza, C. et al. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients]. Biomedica. 30, 410-420 (2010).
-
(2010)
Biomedica
, vol.30
, pp. 410-420
-
-
Isaza, C.1
-
15
-
-
65549085682
-
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
-
Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, pp. 261-266
-
-
Borgiani, P.1
-
16
-
-
79961134642
-
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry
-
Botton, M.R., Bandinelli, E., Rohde, L.E., Amon, L.C. & Hutz, M.H. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br. J. Clin. Pharmacol. 72, 442-450 (2011).
-
(2011)
Br. J. Clin. Pharmacol
, vol.72
, pp. 442-450
-
-
Botton, M.R.1
Bandinelli, E.2
Rohde, L.E.3
Amon, L.C.4
Hutz, M.H.5
-
17
-
-
77957959128
-
An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction
-
Carlquist, J.F. et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30, 358-364 (2010).
-
(2010)
J. Thromb. Thrombolysis
, vol.30
, pp. 358-364
-
-
Carlquist, J.F.1
-
18
-
-
77949873283
-
Genetic and clinical predictors of warfarin dose requirements in African Americans
-
Cavallari, L.H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, pp. 459-464
-
-
Cavallari, L.H.1
-
19
-
-
77954508907
-
CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
-
Cen, H.J. et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br. J. Clin. Pharmacol. 70, 234-240 (2010).
-
(2010)
Br. J. Clin. Pharmacol
, vol.70
, pp. 234-240
-
-
Cen, H.J.1
-
20
-
-
78149256303
-
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
-
Cha, P.C. et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744 (2010).
-
(2010)
Hum. Mol. Genet
, vol.19
, pp. 4735-4744
-
-
Cha, P.C.1
-
21
-
-
84864349523
-
Translational aspects of genetic factors in the prediction of drug response variability: A case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia
-
Chan, S.L., Suo, C., Lee, S.C., Goh, B.C., Chia, K.S. & Teo, Y.Y. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J. 12, 312-318 (2012).
-
(2012)
Pharmacogenomics J
, vol.12
, pp. 312-318
-
-
Chan, S.L.1
Suo, C.2
Lee, S.C.3
Goh, B.C.4
Chia, K.S.5
Teo, Y.Y.6
-
22
-
-
79955486891
-
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients
-
Choi, J.R. et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J. Hum. Genet. 56, 290-295 (2011).
-
(2011)
J. Hum. Genet
, vol.56
, pp. 290-295
-
-
Choi, J.R.1
-
23
-
-
81155137319
-
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation
-
Gong, I.Y. et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS ONE 6, e27808 (2011).
-
(2011)
PLoS ONE
, vol.6
-
-
Gong, I.Y.1
-
24
-
-
77956267130
-
Application of Akaike information criterion to evaluate warfarin dosing algorithm
-
Harada, T. et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb. Res. 126, 183-190 (2010).
-
(2010)
Thromb. Res
, vol.126
, pp. 183-190
-
-
Harada, T.1
-
25
-
-
79251588402
-
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction
-
Kringen, M.K. et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J. Biomed. Biotechnol. 2011, 739751 (2011).
-
(2011)
J. Biomed. Biotechnol
, pp. 739751
-
-
Kringen, M.K.1
-
26
-
-
73649117856
-
Genetic determinants of warfarin dosing in the Han-Chinese population
-
Lee, M.T. et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10, 1905-1913 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1905-1913
-
-
Lee, M.T.1
-
27
-
-
77953745542
-
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
-
Lubitz, S.A. et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8, 1018-1026 (2010).
-
(2010)
J. Thromb. Haemost
, vol.8
, pp. 1018-1026
-
-
Lubitz, S.A.1
-
28
-
-
72849127064
-
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
-
Pautas, E. et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87, 57-64 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, pp. 57-64
-
-
Pautas, E.1
-
29
-
-
77949876162
-
Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort
-
Perini, J.A., Struchiner, C.J., Silva-Assunção, E. & Suarez-Kurtz, G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther. 87, 417-420 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, pp. 417-420
-
-
Perini, J.A.1
Struchiner, C.J.2
Silva-Assunção, E.3
Suarez-Kurtz, G.4
-
30
-
-
77955685235
-
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
-
Sagreiya, H. et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 20, 407-413 (2010).
-
(2010)
Pharmacogenet. Genomics
, vol.20
, pp. 407-413
-
-
Sagreiya, H.1
-
31
-
-
79951682471
-
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients
-
Shahin, M.H. et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics 21, 130-135 (2011).
-
(2011)
Pharmacogenet. Genomics
, vol.21
, pp. 130-135
-
-
Shahin, M.H.1
-
32
-
-
79955711867
-
Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients
-
Singh, O., Sandanaraj, E., Subramanian, K., Lee, L.H. & Chowbay, B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab. Pharmacokinet. 26, 130-136 (2011).
-
(2011)
Drug Metab. Pharmacokinet
, vol.26
, pp. 130-136
-
-
Singh, O.1
Sandanaraj, E.2
Subramanian, K.3
Lee, L.H.4
Chowbay, B.5
-
33
-
-
79957902700
-
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians
-
Suriapranata, I.M. et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med. Genet. 12, 80 (2011).
-
(2011)
BMC Med. Genet
, vol.12
, pp. 80
-
-
Suriapranata, I.M.1
-
34
-
-
63449117825
-
A genome-wide association study confirms VKORC1 CYP2C9 and CYP4F2 As principal genetic determinants of warfarin Dose
-
Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
-
(2009)
PLoS Genet
, vol.5
-
-
Takeuchi, F.1
-
35
-
-
77952550801
-
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism
-
Wells, P.S. et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 125, e259-e264 (2010).
-
(2010)
Thromb. Res
, vol.125
-
-
Wells, P.S.1
-
36
-
-
78650466131
-
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: An Italian retrospective study
-
Zambon, C.F. et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12, 15-25 (2011).
-
(2011)
Pharmacogenomics
, vol.12
, pp. 15-25
-
-
Zambon, C.F.1
-
37
-
-
70349574149
-
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
-
Zhang, J.E. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19, 781-789 (2009).
-
(2009)
Pharmacogenet. Genomics
, vol.19
, pp. 781-789
-
-
Zhang, J.E.1
-
38
-
-
79960616137
-
Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose
-
Zhang, X., Li, L., Ding, X. & Kaminsky, L.S. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439 (2011).
-
(2011)
Drug Metab. Dispos
, vol.39
, pp. 1433-1439
-
-
Zhang, X.1
Li, L.2
Ding, X.3
Kaminsky, L.S.4
-
39
-
-
66549110050
-
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
-
Pérez-Andreu, V. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113, 4977-4979 (2009).
-
(2009)
Blood
, vol.113
, pp. 4977-4979
-
-
Pérez-Andreu, V.1
-
40
-
-
70350754462
-
A genome-wide association study of acenocoumarol maintenance dosage
-
Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758-3768 (2009).
-
(2009)
Hum. Mol. Genet
, vol.18
, pp. 3758-3768
-
-
Teichert, M.1
-
41
-
-
79953777152
-
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
-
Geisen, C. et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur. J. Clin. Pharmacol. 67, 371-381 (2011).
-
(2011)
Eur. J. Clin. Pharmacol
, vol.67
, pp. 371-381
-
-
Geisen, C.1
-
42
-
-
78650680251
-
Dependency of phenprocoumon dosage on polymorphisms in the vKORC1 CYP2C9 and CYP4F2 genes
-
Teichert, M. et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet. Genomics 21, 26-34 (2011).
-
(2011)
Pharmacogenet. Genomics
, vol.21
, pp. 26-34
-
-
Teichert, M.1
-
43
-
-
84861150804
-
Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and metaanalysis
-
Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D. & Sun, Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and metaanalysis. Thromb. Res. 130, 38-44 (2012).
-
(2012)
Thromb. Res
, vol.130
, pp. 38-44
-
-
Liang, R.1
Wang, C.2
Zhao, H.3
Huang, J.4
Hu, D.5
Sun, Y.6
-
44
-
-
62549143945
-
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
-
Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
-
(2009)
Eur. J. Clin. Pharmacol
, vol.65
, pp. 365-375
-
-
Lindh, J.D.1
Holm, L.2
Andersson, M.L.3
Rane, A.4
-
45
-
-
80052962391
-
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
-
Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
-
(2011)
Clin. Pharmacol. Ther
, vol.90
, pp. 625-629
-
-
Johnson, J.A.1
-
46
-
-
78349294600
-
Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
-
French, B. et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
-
(2010)
Trials
, vol.11
, pp. 108
-
-
French, B.1
-
47
-
-
70649084116
-
Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
-
van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1687-1695
-
-
Van Schie, R.M.1
-
48
-
-
84862777241
-
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
-
Anderson, J.L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012).
-
(2012)
Circulation 125
, pp. 1997-2005
-
-
Anderson, J.L.1
-
49
-
-
77949567067
-
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis
-
Yang, L., Ge, W., Yu, F. & Zhu, H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb. Res. 125, e159-e166 (2010).
-
(2010)
Thromb. Res
, vol.125
-
-
Yang, L.1
Ge, W.2
Yu, F.3
Zhu, H.4
-
50
-
-
34447266926
-
Functional polymorphism in human CYP4F2 decreases 20-HETE production
-
DOI 10.1152/physiolgenomics.00003.2007
-
Stec, D.E., Roman, R.J., Flasch, A. & Rieder, M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 30, 74-81 (2007). (Pubitemid 47173292)
-
(2007)
Physiological Genomics
, vol.30
, Issue.1
, pp. 74-81
-
-
Stec, D.E.1
Roman, R.J.2
Flasch, A.3
Rieder, M.J.4
|